October 24, 2018

Researchers investigated almost 200,000 cases of breast cancer: Here’s what they found

Dr. John Bartlett poses for a photo at a table next to a laptop computer displaying lines of code.

 

Research team finds aggressive breast cancers are less frequent than previously thought, and less aggressive breast cancers need more of our attention.

Different subtypes of breast cancer respond to treatment differently and require different treatment approaches. Understanding the distribution of these subtypes and their respective clinical outcomes allows researchers to better understand the disease and identify key research priorities that may have been previously overlooked.

Continue reading – Researchers investigated almost 200,000 cases of breast cancer: Here’s what they found

September 24, 2018

Breaking down barriers to translation: A case of standardization in digital pathology

Jane Bayani In the lab.

OICR takes part in international multicentre study to standardize promising breast cancer digital pathology test

The Ki67 immunohistochemistry assay is a test that can help evaluate the aggressiveness of breast tumours, predict disease outcomes, monitor cancer progression and identify patients who are more likely to respond to a given therapy. Despite its potential to help patients with breast cancer, the analysis of Ki67 has not been widely adopted in the clinic, mostly due to the lack of standardization across laboratories.

Continue reading – Breaking down barriers to translation: A case of standardization in digital pathology

June 4, 2018

New guidelines for HER2 testing in breast cancer

An image of the HER2 protein.

Current HER2 tests help predict which breast cancer patients will respond to HER2-targeted therapies, but sometimes these tests provide unclear results. An Expert Panel of pathologists and cancer researchers, including Dr. John Bartlett from OICR, recently published revised clinical practice guidelines for HER2 testing in breast cancer to help improve clarity of HER2 test results.

Continue reading – New guidelines for HER2 testing in breast cancer

January 25, 2018

The Canadian Data Integration Centre receives new funding to help cancer researchers translate findings to patients

CDI - LogoToronto (January 25, 2018) – The Canadian Data Integration Centre (CDIC) has received $6.4 million in funding from Genome Canada to help the research community translate the biological insights gained from genomics research into tangible improvements for cancer patients.

CDIC is a “one-stop shop” service delivery platform for cancer researchers, helping streamline research by providing coordinated expertise on a broad range of services, including data integration, genomics, pathology, biospecimen handling and advanced sequencing technologies. It is an international leader in genomics, bioinformatics and translational research, supporting some of the world’s largest programs in genomic data analysis, genomic and clinical data hosting, cancer data analyses and access, and the development of algorithms for advanced sequencing technology.

Continue reading – The Canadian Data Integration Centre receives new funding to help cancer researchers translate findings to patients

January 12, 2018

Large-scale study provides clearer picture of recurrence risk for ER-positive breast cancer

Dr. John Bartlett

Endocrine therapy uses hormone antagonists to greatly reduce the risk of disease recurrence in women with early-stage, estrogen-receptor (ER) positive breast cancer. However, the treatment can come with severe side effects. Around 30 per cent of women stop taking the therapy after three years largely due to these negative impacts. Usually patients receive the hormone therapy for five years following initial treatment (e.g., chemotherapy, surgery), but it can also be taken longer-term. A central question facing patients and clinicians is how to balance, in their decision making, the side effects of long-term treatment with the potential reduction in recurrence risk. In short, they want to know: ‘is it worth it?’ 

Continue reading – Large-scale study provides clearer picture of recurrence risk for ER-positive breast cancer

May 3, 2017

Study bringing more precision medicine to Ontario’s cancer patients

A technician holds a blood sample and writes down information.

The advent of genomic sequencing and targeted therapies has opened the door to new ways of diagnosing and treating cancer. The Ontario-wide Cancer Targeted Nucleic Acid Evaluation (OCTANE) program is a new, province-wide initiative supported by OICR that will allow more patients to benefit from these innovations while also helping to advance cancer research in Ontario.

Continue reading – Study bringing more precision medicine to Ontario’s cancer patients

April 13, 2017

Could diagnosing cancer as rare diseases improve outcomes for patients?

Dr. John Bartlett

Breast cancer is the most common form of cancer amongst women in Canada and worldwide, but despite its prevalence, a group of researchers believes that it should often be treated as a rare disease. Doing so would change clinical approaches and improve treatment for patients.

Continue reading – Could diagnosing cancer as rare diseases improve outcomes for patients?

November 23, 2016

OICR and OMPRN celebrate International Pathology Day with educational events

A technician works in OICR pathology lab

On November 16 OICR and the Ontario Molecular Pathology Research Network (OMPRN) joined other organizations around the world celebrating International Pathology Day.

Continue reading – OICR and OMPRN celebrate International Pathology Day with educational events

November 9, 2016

The next generation: Tamara Jamaspishvili

Tamara Jamaspishvili

Men newly diagnosed with prostate cancer face a difficult dilemma: either wait and see how the growth develops and whether it is aggressive, or treat it fully right away and risk the many long-term side effects of treatment. Dr. Tamara Jamaspishvili is a young researcher at Queen’s University in Kingston who is working to change that.

Continue reading – The next generation: Tamara Jamaspishvili

November 4, 2016

Beyond the crime scene: You don’t have to be dead to need a pathologist

Cafe Scientifique banner

Dr. John Bartlett, from the Ontario Institute for Cancer Research, and Dr. Michelle Downes, from Sunnybrook Health Science Centre, will take you into a world of pathology beyond crime scene investigation and into puzzles more complex than an escape room. They will talk about the future of pathology and how this is changing the face of medicine and why a pathologist is considered ‘the doctor’s doctor’.

The Duke of York Pub – November 16, 6-8 p.m.
39 Prince Arthur Avenue, Toronto
near St. George subway station

Register at Eventbrite >

August 17, 2016

Dr. John Bartlett discusses why new retrospective breast cancer study could lead to better diagnosis and treatment for patients

Fu Yan - In the lab.

OICR has announced a new retrospective study that will help to identify mutations for breast cancer, increasing understanding of the disease and potentially leading to better diagnosis in the future. The study is led by Dr. John Bartlett, Director of OICR’s Transformative Pathology Program and Dr. Harriet Feilotter, Department of Pathology and Molecular Medicine, Queen’s University. We spoke to Dr. Bartlett about why this study is important for the future of breast cancer diagnosis and treatment. 

Continue reading – Dr. John Bartlett discusses why new retrospective breast cancer study could lead to better diagnosis and treatment for patients

August 17, 2016

New retrospective study aims to identify mutations to better diagnose breast cancer in the future

Toronto (August 17, 2016) – Mr. Peter Goodhand, President of The Ontario Institute for Cancer Research (OICR), today announced a new collaborative research study in partnership with Thermo Fisher Scientific and Queen’s University to help bring more targeted diagnosis and treatment to breast cancer patients in the future.

Continue reading – New retrospective study aims to identify mutations to better diagnose breast cancer in the future

Next Page »